Essais liés11clinical trials
VilleTorontolocalisation
PaysCanadalocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06138639

Ouvrir le site du centre

Essais cliniques associés

11
MoléculeIndication / populationPhaseNCTTitreStatut
Ocrelizumab SEP Phase 3 NCT05123703 Operetta 2 — A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) ACTIVE_NOT_RECRUITING
Erenumab Dose 1 Migraine Phase 3 NCT03832998 OASIS(CM) — Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine COMPLETED
SGT-003 Myopathies Phase 1/2 NCT06138639 A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) RECRUITING
RGX-202 Myopathies Phase 2/3 NCT05693142 AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) ACTIVE_NOT_RECRUITING
PF-06939926 Myopathies Phase 3 NCT04281485 Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy ACTIVE_NOT_RECRUITING
ASP2957 Myopathies Phase 1/2 NCT07052929 Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators RECRUITING
CC-97540 Lupus Phase 2 NCT07015983 A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) ACTIVE_NOT_RECRUITING
Obinutuzumab Lupus Phase 2 NCT05039619 POSTERITY — A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants RECRUITING
Erenumab Dose 1 Migraine Phase 3 NCT03836040 OASIS(EM) — Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine ACTIVE_NOT_RECRUITING
Clemizole HCl Épilepsie Phase 3 NCT04462770 ARGUS — A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome RECRUITING
Epidiolex 100 mg/mL Oral Solution Épilepsie Phase 4 NCT06924827 CANN-SWITCH — A Study to Investigate the Transition of Children From 'Artisanal" Cannabidiol (CBD) to Epidiolex NOT_YET_RECRUITING